secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K/A
Filed at:   2026-08-14T20:10:15+00:00
Accession:  0001193125-26-352233
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma details COO Kling's exit: unvested equity canceled, $50k/mo advisor fee
--------------------------------------------------------------------------------

- Douglas Kling resigned as COO effective Aug 14, 2026, to become CEO of another clinical-stage biotech.
- Unvested stock options and RSUs canceled as of separation date, except those vesting on continued service through May 14, 2027.
- Kling entered Advisor Agreement with NewAmsterdam Pharma B.V. for $50,000/month plus expenses for PREVAIL trial and other clinical programs.
- Advisor Agreement runs to May 14, 2027; includes confidentiality, non-disparagement, non-solicitation covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/0001193125-26-352233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/nams-20260716.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer